This segment focuses on the discovery and development of small molecule therapies that target p53 mutations, a common driver of cancer development. PMV Pharmaceuticals employs a precision oncology approach, creating tumor-agnostic therapies designed to restore wild-type p53 function. Key research and development activities include preclinical studies, lead optimization, and clinical trials for drug candidates like PC14586, which targets the Y220C mutation. The segment leverages structural biology, medicinal chemistry, and advanced screening technologies to identify and develop novel compounds. By addressing p53 mutations, PMV aims to provide effective treatments for a broad range of cancer types, improving patient outcomes and quality of life. Future opportunities include expanding the pipeline with additional p53-targeting therapies and exploring combination therapies with existing cancer treatments. The segment is subject to rigorous regulatory oversight, including FDA approval processes and clinical trial protocols.